%D8%A8%D8%B1%D9%88%D9%85%D9%88%D9%83%D8%B1%D9%8A%D8%A8%D8%AA%D9%8A%D9%86%D8%A8%D8%B1%D9%88%D9%85%D9%88%DA%A9%D8%B1%DB%8C%D9%BE%D8%AA%DB%8C%D9%86BromocriptinBromocriptinBromocriptineBromocriptina%D8%A8%D8%B1%D9%88%D9%85%D9%88%DA%A9%D8%B1%DB%8C%D9%BE%D8%AA%DB%8C%D9%86BromocriptineBromokriptinBromocriptina%E3%83%96%E3%83%AD%E3%83%A2%E3%82%AF%E3%83%AA%E3%83%97%E3%83%81%E3%83%B3BromokryptynaBromocriptina%D0%91%D1%80%D0%BE%D0%BC%D0%BE%D0%BA%D1%80%D0%B8%D0%BF%D1%82%D0%B8%D0%BDBromokriptinBromokriptinBromokriptin%D0%91%D1%80%D0%BE%D0%BC%D0%BE%D0%BA%D1%80%D0%B8%D0%BF%D1%82%D0%B8%D0%BDQ413581%E6%BA%B4%E9%9A%B1%E4%BA%AD
about
5-hydroxytryptamine receptor 2ADopamine receptor D25-hydroxytryptamine receptor 2C5-hydroxytryptamine receptor 6Dopamine receptor D1Dopamine receptor D35-hydroxytryptamine receptor 1A5-hydroxytryptamine receptor 1DDopamine receptor D5Adrenoceptor alpha 2B5-hydroxytryptamine receptor 1BDopamine receptor D45-hydroxytryptamine receptor 2BAdrenoceptor alpha 2CAdrenoceptor alpha 2A
P129
The Therapeutic Effect of Bromocriptin in Patients With Primary AldosteronismQR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 DiabetesBromocriptine for Patients With Schizophrenia and Impaired Glucose ToleranceEfficacy of Bromocriptine For Fever Reduction in Acute Neurologic InjuryBromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 DiabetesBromocriptine in the Treatment of Peripartum CardiomyopathyPharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus SubjectsBromocriptine and Insulin SensitivityDopaminergic Effects on Brown Adipose TissueEffect of Cycloset on Glycemic Control When Added to GLP-1 Analogue TherapyTo Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related ParkinsonismOphthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's DiseaseVaginal Bromocriptine for Treatment of AdenomyosisPramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's DiseaseA Model to Identify Specific Predictors of Spatial Neglect RecoveryEffect of Bromocriptine on Left Ventricular Function in Women With Peripartum CardiomyopathyFed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate TabletsFed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mgMOTION, Safinamide in Early IPD, as add-on to Dopamine AgonistDopamine Action on Metabolism in Relation to GenotypeEvaluation of Bromocriptine, Metoprolol and Tamsulosin in Eyes With Non-Central DMESafety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's DiseaseEffect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot StudyBromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune TreatmentSafety and Tolerability Study of Cycloset in Treatment of Type 2 DiabetesRisperidone-Induced Hyperprolactinemia Treated With BromocriptineBromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes SubjectsEfficacy and Safety of Cycloset® Compared With Placebo When Added to MetforminRandomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's DiseasePhase II Study of Stereotypes and Mental Retardation: Neurobiological BasisDopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT InhibitorSatisfaction of Patients With the Chosen Method of Inhibition of LactationEfficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation SyndromeDopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia NervosaAcute Olanzapine and Lipid ResponseManagement of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid ResponseRepurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease
P4844
Q1949517-11FDD7D0-F88C-4E12-BDA8-0ADA01160FA4Q2034004-E5C7F0B1-8D83-4809-93FD-071AA0218469Q21108118-F520F7B5-C421-41AA-BCF5-02EC731974CEQ21109363-3010D4F1-3EDD-4B93-A263-F45DCB1A0BCFQ21110867-E0C7E62F-3238-4DE3-B55B-BBF98B99B442Q21110872-6A9B1635-B1F6-4BFD-B10F-8AC9FF0C2C47Q21115043-4CBE8BFE-89F8-4A50-8149-3F43C98DB12FQ21115046-2F88F7B0-EC1A-4F1F-B739-0486198458C7Q21131500-7B5D9E77-0B25-4AB0-BDBC-D6FF4561185CQ21141045-587453AE-435E-4A9B-AFE5-F27A55DFAA53Q288797-6A62F6D4-01B5-460B-BE41-095222B784D9Q308856-85B275CC-955A-4EEA-8B61-2E28A6E49636Q4639596-4E27AB92-2CAC-4464-83BA-1D5F6EDFF44AQ4734891-2D7FFF05-F709-4FDC-A6BB-4BB9640401FDQ4734892-D1B5CF43-AADA-4153-BD77-516D0BB872C4
P129
Q11085-23FD4DFC-0AAC-46EF-97E6-63B899997BACQ1424956-A619C72A-3FE2-46FB-B764-656F8FEAD511Q1433936-0F78A6B8-2FEA-4127-9C13-74CAF95955D2Q179399-8BC31801-CE4F-4680-9B73-388A47A104D0Q18556776-9649F490-1BC5-4ADE-BDBE-3D61535D9570Q189580-ECD75648-3047-4283-9F72-6E92899EA5E9Q334655-7E0E12BD-84D3-47EC-829C-ACA250C8E1EEQ938107-3A5CB267-E384-47DC-86E0-ADB1F32A1291Q954831-1A31EF07-716C-4754-BF6E-0B587B2A939E
P2176
Q61920935-1222C281-E96D-4BB6-A586-CB023D213739Q61955301-2222107B-DA82-4E2B-B5D3-13E9E05FFF7EQ63396929-D7102428-6A15-4B31-B362-658D00ABCFF9Q63400025-949122F3-6027-4874-AC41-247B006B76F4Q63813389-DD840A60-D31B-4565-BB1A-12B17BD0EDD0Q64217127-66ACBDE2-79B8-40A2-8529-DF6B7D94A8C2Q64222001-9CBF1219-0C5F-4D85-8352-78852A6BF9A8Q64394496-597C77EE-0E50-4A5C-98F7-D6AE2171898BQ64394500-578C7FF9-7AA7-4BDB-9E3C-397F4270F8C7Q64599397-FB20F625-25D0-4087-8B6A-119FDED48714Q64600719-025CD5DE-678B-4195-B4B1-0F71193DA5A4Q64607164-DAC9A04B-BAA4-46CE-8E99-E327A05F0813Q64625115-336675E7-CB7F-429D-8EB0-B5424B3C28EBQ64643294-C3B0A61B-EABE-43B5-99D3-CA1B0FD17291Q64661584-85A95427-314E-431D-83DB-5B3EB6D882CBQ64693131-223C6D09-9979-4595-8226-84F6749EAE78Q64720647-39844A79-EE08-4A18-98DE-99C881BC0865Q64720872-60181EE9-7743-410F-917A-744BEC2F4E7AQ64725147-208E4C69-486A-4902-8201-EE6657BB6A14Q64801573-27EBF8FC-570A-4FA0-B16F-94571356B3AEQ64804968-BA44FC9B-37C2-439B-AB31-0FBB61B96545Q65354060-FBF59E13-A3FC-4948-87F1-A3A3746AAF8CQ65359381-13D17D7E-D670-431E-8AF9-371341989741Q65364076-9556AECD-7B3C-4036-98DB-F33C4120F624Q65388691-0CE43354-DDDF-4C36-9C8C-8929CC52D37DQ65391208-A9421600-9B15-4B1E-9BED-ABC5528E21BCQ65398972-42E97B0A-74FE-4666-B01E-F4067C61946FQ65471604-B7CD8F97-D5A6-42B1-8CD7-845DD254AB4DQ65542961-34C56BB1-480D-4AE6-8BEE-F44A457B745EQ66062092-057BF168-33DD-4617-B843-9296484EFEBBQ66081202-F84A5505-7409-4D11-A7EC-B6867CABD8D9Q66388643-50C533C6-DCCF-4BE1-A41F-53C070BAD635Q66397517-4E0B490F-58C3-49DA-A8D4-702EA8D3EAADQ74276212-F9644D59-0292-4F92-8929-F6E5A70DCC65Q76980835-ACB0EA1C-44C7-4380-928C-8573D69C3FB1Q93581714-224B5D19-A291-4EAB-8E05-5A9D084BAE53Q96055686-316B0A13-4634-4F70-B428-B6F21A99C99D
P4844
description
Medication which has significant effects on dopamine levels in the brain.
@en
Prolaktina-jariapena kontrolat ...... n tratamenduan erabiltzen dena
@eu
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
name
Bromocriptin
@de
Bromocriptina
@es
Bromocriptine
@nl
Bromocriptine
@vi
Bromokriptin
@hu
Bromokriptin
@sh
Bromokriptin
@sr-el
Bromokriptin
@sv
Bromokryptyna
@pl
bromocriptin
@cy
type
label
Bromocriptin
@de
Bromocriptina
@es
Bromocriptine
@nl
Bromocriptine
@vi
Bromokriptin
@hu
Bromokriptin
@sh
Bromokriptin
@sr-el
Bromokriptin
@sv
Bromokryptyna
@pl
bromocriptin
@cy
altLabel
(5'alpha)-2-bromo-12'-hydroxy- ...... opyl)-3',6',18-trioxoergotaman
@en
(5'alpha)-2-bromo-12'-hydroxy- ...... opyl)ergotaman-3',6',18-trione
@cy
(5'alpha)-2-bromo-12'-hydroxy- ...... opyl)ergotaman-3',6',18-trione
@en
(5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman
@cy
(5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman
@en
2-Bromo-alpha-ergocryptine
@en
2-Bromo-alpha-ergokryptin
@en
2-Bromo-alpha-ergokryptine
@en
2-bromo-alpha-ergocryptine
@cy
2-bromo-alpha-ergocryptine
@en
prefLabel
Bromocriptin
@de
Bromocriptina
@es
Bromocriptine
@nl
Bromocriptine
@vi
Bromokriptin
@hu
Bromokriptin
@sh
Bromokriptin
@sr-el
Bromokriptin
@sv
Bromokryptyna
@pl
bromocriptin
@cy